Pyrimidine metabolism

Pyrimidine metabolism is a complex biological pathway responsible for the de novo synthesis, salvage, and degradation of pyrimidine nucleotides, which are essential building blocks for DNA and RNA. The de novo pathway involves the production of uridine monophosphate (UMP) from simple precursors like aspartate and carbamoyl phosphate, while the salvage pathway recycles pre-existing bases and nucleosides [Source: Wikipedia, KEGG]. Because rapidly dividing cells, such as cancer cells and activated T-cells, have a high demand for nucleotides, this pathway is a critical focus for therapeutic intervention. Drugs like 5-Fluorouracil and Gemcitabine inhibit specific enzymes within this pathway to stop tumor growth, while drugs like Leflunomide are used in autoimmune diseases to suppress immune cell expansion [Source: PubChem, PubMed]. However, as a metabolic pathway rather than a single molecule, it encompasses many distinct enzymes (e.g., DHODH, UMPS, TYMS) that serve as individual drug targets. Disruptions in this pathway can lead to severe metabolic disorders or toxicities, particularly if degradative enzymes like dihydropyrimidine dehydrogenase are deficient [Source: NIH/GARD].

Other names

Pyrimidine biosynthesisPyrimidine catabolismPyrimidine salvage pathwayDe novo pyrimidine synthesis

Drugs targeting this pathway typically act as antimetabolites or enzyme inhibitors. They work by inhibiting key enzymes such as Dihydroorotate dehydrogenase (DHODH), Thymidylate synthase (TS), or Ribonucleotide reductase (RNR), thereby depleting the pool of pyrimidine nucleotides (cytidine, thymidine, and uridine) required for DNA and RNA polymerase activity, ultimately leading to cell cycle arrest or apoptosis [Source: NIH/NCBI, StatPearls].